Article
Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype.
Clinical and translational medicine - 1 Nov 2022
Albrecht Lea Jessica, Höwner Anna, Griewank Klaus, Lueong Smiths S, von Neuhoff Nils, Horn Peter A, Sucker Antje, Paschen Annette, Livingstone Elisabeth, Ugurel Selma, Zimmer Lisa, Horn Susanne, Siveke Jens T, Schadendorf Dirk, Váraljai Renáta, Roesch Alexander
Abstract excerpt
BACKGROUND: Plasma-derived tumour-specific cell-free nucleic acids are increasingly utilized as a minimally invasive, real-time biomarker approach in many solid tumours. Circulating tumour DNA of melanoma-specific mutations is currently the best studied liquid biopsy biomarker for melanoma. However, the combination of hotspot genetic alterations covers only around 80% of all melanoma patients. Therefore,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.